Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1474

8-Year Follow-up Study: Differences Between HLA-B27 Positive and Negative Children with Juvenile Idiopathic Arthritis in Finland

9:00AM-11:00AM: Abstract Number: 1469

A Comparison of Pain and Disability, and Their Association Between Juvenile Primary Fibromyalgia Syndrome and Pediatric Rheumatic Diseases: Results from the Childhood Arthritis and Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 1481

A Description of the Transition Aged Population in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 1470

A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects

9:00AM-11:00AM: Abstract Number: 1480

Adiposity in Children with Juvenile Psoriatic Arthritis (JPsA)

9:00AM-11:00AM: Abstract Number: 1457

An Organ Based Diagnostic Approach to Macrophage Activating Syndrome in Children Demonstrates Impaired Reticuloendothelial System Clearance

9:00AM-11:00AM: Abstract Number: 1463

Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1464

Assessment of Left Ventricle Functions in Children with Familial Mediterranean Fever with Tissue Doppler and Strain Echocardiography

9:00AM-11:00AM: Abstract Number: 1466

Assessment of Transition Readiness in Adolescents and Young Adults with Chronic Health Conditions

9:00AM-11:00AM: Abstract Number: 1458

Association of Chronic, Extreme Elevation of Serum IL-18 with the Development of Macrophage Activation Syndrome in a Cohort of Autoinflammatory Disease Patients: A Potential Diagnostic Biomarker?

9:00AM-11:00AM: Abstract Number: 1460

Association of Vitamin D Receptor Polymorphism with Juvenile Idiopathic Arthritis (JIA)

9:00AM-11:00AM: Abstract Number: 1450

Clostridium Difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort

9:00AM-11:00AM: Abstract Number: 1478

Comparison of JIA and RA Patients in the National Data Bank for Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1484

Development and Validation of Juvenile Autoinflammatory Disease Multidimensional Assessment Report (JAIMAR)

9:00AM-11:00AM: Abstract Number: 1485

Efficacy of Yttrium-90 Radiosynovectomy in Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome

9:00AM-11:00AM: Abstract Number: 1454

Familial Mediterranean Fever in Childhood: a Single Center Experience

9:00AM-11:00AM: Abstract Number: 1462

Farber Disease: Important Differential Diagnostic Information for JIA and Other Inflammatory Arthritis Phenotypes Is Revealed By Data from the Largest Clinical Cohort to Date

9:00AM-11:00AM: Abstract Number: 1475

Fatigue, Quality of SLEEP and PAIN in Children with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1467

Health Related Quality of Life Is Reduced in Pediatric Patients with Juvenile Idiopathic Arthritis and Juvenile-Onset Fibromyalgia

9:00AM-11:00AM: Abstract Number: 1476

Improvement of the Long-Term Outcome in Greek Adult Patients with Juvenile Idiopathic Arthritis in the 21st Century

9:00AM-11:00AM: Abstract Number: 1472

Incidence and Mortality in a Population-Based Cohort of Patients with Juvenile Arthritis 1960-2013

9:00AM-11:00AM: Abstract Number: 1461

Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1473

Juvenile Psoriatic Arthritis Manifestations in a Cohort of 361 Patients from US and Canada

9:00AM-11:00AM: Abstract Number: 1455

Juvenile Spondyloarthropathies: a Single Center Experience

9:00AM-11:00AM: Abstract Number: 1446

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry

9:00AM-11:00AM: Abstract Number: 1456

Macrophage Activation Syndrome and Familial Hemophagocytic Lymphohistiocytosis: Is Their Clinical Phenotype Really Similar?

9:00AM-11:00AM: Abstract Number: 1465

Musculoskeletal Anomalies in Children with Trisomy 21

9:00AM-11:00AM: Abstract Number: 1451

Neurologic Findings and Serial Neuroimaging in Patients with Linear Scleroderma En Coup De Sabre (ECDS) and Parry-Romberg Syndrome (PRS)

9:00AM-11:00AM: Abstract Number: 1477

Patterns of Enthesitis and Arthritis in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1452

Pauciimmune and Immune Mediated Pulmonary Capillaritis in Children

9:00AM-11:00AM: Abstract Number: 1483

Pediatric Rheumatologists’ Perceptions of Career Satisfaction, Confidence in Fulfilling Their Roles, and Burn-out

9:00AM-11:00AM: Abstract Number: 1471

Phenotypic Differences Between HLA-B27 Positive and Negative Children with Enthesitis-Related Arthritis

9:00AM-11:00AM: Abstract Number: 1445

Physicians’ Perspectives on the Diagnosis and Treatment of Chronic Nonbacterial Osteomyelitis

9:00AM-11:00AM: Abstract Number: 1447

Positive Power Doppler Signal Increases the Risk of Clinical Flare of Patients with Juvenile Idiopathic Arthritis in Clinical Remission: A Prospective Study

9:00AM-11:00AM: Abstract Number: 1448

Progressive Pseudorheumatoid Arthropathy of Childhood (PPAC) – a Single Center Case Series

9:00AM-11:00AM: Abstract Number: 1479

Qualitative Assessment of Patient Important Long-Term Outcomes in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1459

Racial Comparisons of Children with Idiopathic Uveitis: Results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 1453

Surveillance of Periodic Fever Syndromes in Canada

9:00AM-11:00AM: Abstract Number: 1482

Temporomandibular Pain in Patients with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1449

The Effect of IL-1 Receptor Antagonist Anakinra (Kineret®) on Measures of Central Nervous System Inflammation and Headaches in Pediatric Patients with Severe Cryopyrin-Associated Periodic Syndromes

9:00AM-11:00AM: Abstract Number: 1468

The Proposed Outcome Parameters of the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) with Uveitis Disability VAS Score Correspond Significantly with Uveitis “Classicaly Assessed” Uveitis Activity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].